Related Experiment Video

Updated: Nov 6, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials

Azita H Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh

    Medrxiv : the Preprint Server for Health Sciences
    |May 11, 2021
    PubMed

    Insights

    Lipid-modulating agents show promise for treating COVID-19 by reducing inflammation and potentially inhibiting viral entry. Ongoing trials explore their use in managing the disease and its associated dyslipidemia.

    Area of Science:

    • Cardiovascular Medicine
    • Infectious Diseases
    • Pharmacology

    Background:

    • COVID-19 involves systemic inflammation, endothelial dysfunction, and multi-organ issues.
    • Dyslipidemia, characterized by low HDL and high triglycerides, is linked to poorer COVID-19 outcomes.
    • Lipid-modulating agents may offer therapeutic benefits by disrupting viral entry or reducing inflammation.

    Approach:

    • Systematic search identified 40 randomized controlled trials (RCTs) on lipid-modulating agents for COVID-19.
    • Trials included statins (17), omega-3 fatty acids (14), fibrates (3), niacin (5), and dalcetrapib (1).
    • This manuscript reviews completed and ongoing RCTs and their clinical implications.

    Key Points:

    • Lipid-modulating agents may inhibit SARS-CoV-2 entry via lipid raft disruption.
    • These agents can potentially ameliorate COVID-19-associated inflammation and endothelial activation.
    • Specific lipid profiles in COVID-19 patients correlate with disease severity.

    Conclusions:

    • The review summarizes RCTs investigating lipid-modulating agents in COVID-19 management.
    • Findings will inform clinical practice regarding the use of these agents in COVID-19 patients.
    • Further research is ongoing to establish the definitive role of lipid modulators in COVID-19 therapy.

    More Related Videos

    Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss07:03

    Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

    Published on: July 19, 2024

    1.2K
    Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells10:02

    Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

    Published on: June 10, 2022

    2.4K

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    1.1K
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    89
    Lipid-derived Compounds in the Human Body01:31

    Lipid-derived Compounds in the Human Body

    Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
    Fat-soluble Vitamins
    Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
    5.7K
    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    441
    Lipid Absorption01:24

    Lipid Absorption

    Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
    These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
    1.9K
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    302